Women's Health · LP-103
Folic acid Tablets
Generic medicine development record. Review the proposed presentation and the professional reference information below.
Development record
- Portfolio reference
- LP-103Women's Health
- Generic identity
- Folic acidTablet
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Ingredient reference
Record identity and reference background.
- Portfolio reference
- LP-103
- Generic ingredient
- Folic acid
- Dosage form
- Tablet
- Proposed strength
- 400 mcg; 1 mg; 5 mg
- Proposed pack
- Blister 10 x 10 tablets
- Portfolio category
- Women's Health
About Folic acid
Folic acid is a form of folate, a vitamin required for normal cell division and red-blood-cell production. It has established roles in defined folate-deficiency management and pregnancy-related prevention programmes. These uses require different clinical contexts; tablet strength alone does not determine the reason for treatment. A medicine containing folic acid should be assessed alongside diet, other supplements and the cause of any suspected deficiency.
How to read this profile
Scientific information relates to the ingredient and dosage-form context. It is not approved Luang Pharma labelling, a clinical recommendation, or evidence of equivalence to a referenced product. Multiple strengths or presentations represent separate proposed variants and must not be treated as interchangeable.
02 · Professional background
Scientific & clinical reference
Read the clinical context, selected safety considerations and presentation-specific information below.
Clinical context and therapeutic role
Professional assessment distinguishes routine supplementation from treatment of documented deficiency and from folate support alongside particular medicines. Pregnancy planning and specific higher-risk situations require the relevant clinical guidance. Symptoms such as fatigue or anaemia should not automatically be attributed to folate deficiency. The catalogue includes several tablet strengths, and the appropriate authorized presentation must be selected from verified product information rather than a general educational page.
Important safety considerations
Folic acid is generally well tolerated, but gastrointestinal symptoms and allergic reactions can occur. Vitamin B12 deficiency is an important diagnostic consideration because folate can correct some blood abnormalities without addressing neurological injury. Review antiepileptic medicines and other therapies that affect folate handling. Patients receiving methotrexate need a clinician-defined plan; folic acid and folinic acid are different medicines and must not be interchanged on the basis of similar names.
These are selected considerations, not a complete list. Use the current instructions or approved label for the exact authorised product and seek appropriate professional advice.
Presentation, handling and storage
This is a solid oral folic acid entry with several strengths. Microgram and milligram units must be displayed distinctly. Tablet scoring, excipient composition and suitability for splitting are not established by the catalogue and need label confirmation.
Keep the medicine in the labelled original pack with its leaflet. Check the expiry date and pack integrity before dispensing. The authorized label must determine storage temperature, protection from moisture or light, and disposal; no shelf life or in-use period can be established from a catalogue entry.
Final composition, instructions, shelf life and storage conditions are not established by this portfolio entry. They must come from the controlled documentation for the specific product.
Points for professional review
Confirm the purpose of supplementation, pregnancy-related needs, relevant blood findings, vitamin B12 assessment when indicated and interactions. Use the actual authorized label for each strength.
03 · Product enquiry
Documentation & regulatory status
Evidence status
What is established — and what remains open
This record has received an editorial evidence-layer review. The review separates catalogue facts from unresolved product-specific fields and external context; it is not medical, regulatory or market-authorisation approval.
Layer 01
Controlled catalogue facts
- Generic ingredient
- Folic acid
- Dosage form / presentation
- Tablet
- Catalogue strength
- 400 mcg; 1 mg; 5 mg
- Catalogue pack
- Blister 10 x 10 tablets
- Portfolio category
- Women's Health
Layer 02
Unresolved product-specific fields
- Exact release/coating/scoring characteristics and formulation-specific administration instructions require controlled product documentation where applicable.
- Approved indication, patient eligibility and dosing are not established by this portfolio record.
- Registration, manufacturing/site status, supply availability, storage conditions and shelf life remain product- and market-specific evidence items.
Layer 03
Attributed external context
- NHS: folic acidpublic health service medicine information
These references provide scientific or regulatory context only. They are not Luang Pharma product labelling, registration, manufacturing evidence, equivalence evidence or confirmation of supply.
Layer 04
Documents required to close the record
- Controlled product master/specification confirming the exact ingredient identity, dosage form, strength variant and pack mapping.
- Destination-market authorisation or other lawful supply-route evidence plus the approved label/leaflet/IFU, where applicable.
- Product-specific composition/excipient, storage, shelf-life and pack-control documentation.
- Manufacturing-site and supply-status evidence before any public claim of installed capability, registration, availability or equivalence.
For LP-103, identify the destination country, intended professional use, proposed presentation and the role of your organisation. The appropriate supply route and available documentation must be confirmed for that case.
- Confirm the legal entity, manufacturing site and authorised scope for the proposed supply chain.
- Confirm product registration or another lawful route, approved labelling and the applicable destination requirements.
- Request relevant product information, specifications and supporting evidence through the company contact.
- Confirm storage, transport, traceability, complaints and safety-reporting responsibilities before any agreement.
The public catalogue extends beyond the initial planned facility modules. A listing does not mean that the dosage form is installed, qualified or licensed at Boten.
04 · External sources
Sources and further reading
External sources are provided for reference. Their authors do not endorse Luang Pharma, and another product’s authorisation does not transfer to this portfolio record. Source availability and wording can change.
Professional enquiries
Request product-specific evidence for LP-103.
State the exact presentation, organisation, destination and evidence needed. This public record is not an offer of supply.